Cargando…
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study
BACKGROUND: To evaluate the efficacy and safety of two individualized ranibizumab retreatment schemes in neovascular age-related macular degeneration. METHODS: Patients (N = 671) were randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg injections, then retreatment guided by either b...
Autores principales: | Staurenghi, Giovanni, Garweg, Justus G., Gerendas, Bianca S., Macfadden, Wayne, Gekkiev, Boris, Margaron, Philippe, Dunger-Baldauf, Cornelia, Kolar, Petr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953154/ https://www.ncbi.nlm.nih.gov/pubmed/31918685 http://dx.doi.org/10.1186/s12886-019-1251-6 |
Ejemplares similares
-
Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017) -
RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study
por: Holz, Frank G., et al.
Publicado: (2020) -
Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021) -
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
por: Hamilton, Robin D., et al.
Publicado: (2020) -
REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study
por: Koh, Adrian, et al.
Publicado: (2020)